Core Insights - Beyond Air, Inc. has announced a leadership change with Steve Lisi resigning as CEO and Robert Goodman appointed as the new CEO effective March 27, 2026 [1][2][3] Leadership Transition - Steve Lisi has led Beyond Air for nine years, successfully guiding the development and market launch of the LungFit PH system [2] - Robert Goodman, previously the Chief Commercial Officer, has been appointed as CEO, bringing extensive experience in commercial and operational roles within the healthcare sector [1][3][4] - The company anticipates a seamless transition with no disruption to operations or customer relationships [6] Company Background - Beyond Air is focused on utilizing nitric oxide to improve patient outcomes in respiratory illnesses, neurological disorders, and solid tumors [7] - The company has received FDA approval and CE Mark for its LungFit PH system, aimed at treating neonates with hypoxic respiratory failure [7]

Company Overview - Integer Holdings Corporation is a prominent global contract manufacturer in the medical device sector, utilizing its scale and technical expertise to provide high-value solutions to OEM customers [1] - The company has a diversified product range and operates in multiple regions, enabling it to support complex medical procedures and adapt to changing healthcare demands [1] Insider Trading Activity - On March 13, 2026, Tom Thomas, VP, Corporate Controller, reported the sale of 825 shares of Integer Holdings Corporation common stock in an open-market transaction [4] - This sale represented 15.85% of Thomas's direct holdings at the time, based on the share counts disclosed in the Form 4 [3] - The transaction is viewed as routine liquidity management rather than a sign of increased selling pressure, as it reflects ongoing liquidity management amid declining share capacity [2][5] Financial Performance - Integer reported approximately $1.85 billion in full-year 2025 sales, marking an 8% increase year-over-year, with adjusted operating income rising by 13% and adjusted EPS climbing by 21% [6] - Growth has been primarily driven by the cardio and vascular segment, benefiting from new product introductions and acquisitions, while other segments show mixed performance [6] Leverage and Financial Concerns - The company's leverage remains high at nearly 3.0 times EBITDA, with total debt increasing by $195 million to $1.185 billion at the end of the year [7] - The critical question for investors is whether Integer can convert consistent revenue growth into sustained margin expansion and improve its balance sheet, which is deemed more significant than the recent insider transaction [7]

Core Viewpoint - Royal Philips announced proposed appointments and re-appointments for its Supervisory Board, including the appointment of John DeFord and the re-appointments of Paul Stoffels, Herna Verhagen, and Sanjay Poonen, while Roy Jakobs is proposed for re-appointment as President/CEO [8][11][15]. Group 1: Board Appointments - John DeFord is proposed as a new member of the Supervisory Board, recognized for his extensive experience in the medical device industry and expertise in regulatory affairs and quality systems [9][10]. - Paul Stoffels, Herna Verhagen, and Sanjay Poonen are recommended for re-appointment due to their valuable contributions and strong track records in medical and health technology [12][15]. - Marc Harrison will step down from the Supervisory Board after his second term, having served since 2018 [13][14]. Group 2: Leadership and Strategic Direction - Roy Jakobs is proposed for re-appointment as President/CEO, reflecting the Supervisory Board's confidence in his leadership and the progress made since 2022 [15]. - The continued service of the re-appointed members is expected to strengthen the Supervisory Board as Philips advances its strategic priorities, including innovation and patient safety [12][15]. Group 3: Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, with 2025 sales of EUR 18 billion and approximately 64,800 employees [18].

Core Viewpoint - Royal Philips is proposing new appointments and re-appointments to its Supervisory Board, including the appointment of John DeFord and the re-appointment of existing members, as part of its strategic focus on innovation and leadership in health technology [2][5][9]. Group 1: New Appointment - John DeFord is proposed as a new member of the Supervisory Board, recognized for his extensive experience in the medical device industry and expertise in regulatory affairs and quality systems [2][3]. - DeFord currently serves as Chairman and CEO of Samothrace Medical Innovations and has held senior leadership roles at Becton Dickinson and C.R. Bard [4]. Group 2: Re-appointments - The Supervisory Board recommends the re-appointment of Paul Stoffels, Herna Verhagen, and Sanjay Poonen, citing their valuable contributions and strong track records in medical and health technology [5][6]. - These re-appointments are seen as essential for advancing Philips' strategic priorities, including innovation and patient safety [6]. Group 3: Leadership Changes - Marc Harrison will step down from the Supervisory Board after serving two consecutive terms since 2018 [7]. - Roy Jakobs is proposed for re-appointment as President/CEO and Chairman, reflecting the Supervisory Board's confidence in his leadership and the progress made since 2022 [9]. Group 4: Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, generating EUR 18 billion in sales in 2025 and employing approximately 64,800 people [14].

KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the third quarter fiscal 2026, which ended January 31, 2026. Financial Highlights Generated revenue of $24.6 million in Q3 FY26, an increase of 63% compared to the prior year period.Expanded gross margin to 52.6% in Q3 FY26 compared to 43.4% in the prior year period.Increased FY26 revenue guidance to $93 m ...

NeuroOne Medical Technologies FY Conference Summary Company Overview - **Company**: NeuroOne Medical Technologies Corporation - **Ticker**: NasdaqCM: NMTC - **Technology**: Developed a thin film electrode platform technology for various neurological conditions including epilepsy, Parkinson's disease, back pain, and drug delivery for gene and cell therapies [3][4] Core Points and Arguments - **Device Portfolio**: - Four devices with FDA 510(k) clearance: three for brain-related applications and one for facial pain [4] - Key products include the OneRF Ablation System, which is the only FDA-cleared device for both diagnostic and therapeutic use [8][9] - The OneRF Trigeminal Nerve Ablation System targets trigeminal neuralgia, a condition with a high suicide rate among patients [10][11] - The spinal cord percutaneous paddle lead is designed for lower back pain, offering broader stimulation with less energy [12][13] - Basivertebral nerve ablation (BVNA) technology is in development, targeting lower back pain procedures [14][15] - Drug delivery technology capable of recording brain activity and stimulating tissue during therapy [16][17] - **Market Opportunity**: - Multi-billion dollar market potential for all devices, with spinal cord stimulation generating $3-4 billion in revenue [6] - Epilepsy, drug delivery, and basivertebral nerve ablation are expected to grow into billion-dollar businesses [6] - **Partnerships**: - Current partnerships with Mayo Clinic and Zimmer Biomet, with potential for additional collaborations [4][5] - Received $8.5 million in licensing fees from Zimmer Biomet for exclusive distribution rights [5] - **Financial Overview**: - Cash on hand as of December 31: $3.6 million, with accounts receivable of $2.7 million [20] - Product revenue for the fiscal first quarter: $2.9 million, a 5.5% sequential increase [20] - Expected product revenue for the year: at least $10.5 million, a minimum of 17% increase over the prior year [21] - **Upcoming Catalysts**: - Continued revenue growth for the RF brain ablation system [23] - Full launch of trigeminal nerve ablation system expected next quarter [23] - Potential licensing agreements and commercialization for drug delivery [23] Additional Important Content - **Regulatory Path**: - Preparing for ISO 13485 certification to facilitate international distribution [6][21] - The regulatory path for BVNA is expected to be a 510(k) [15] - **Safety and Efficacy**: - No reported adverse events in epilepsy procedures using the OneRF system, with many patients experiencing significant seizure reduction [9][28] - A registry has been established to collect data on patient outcomes, which is critical for expanding device utilization [27][29] - **Leadership Experience**: - Team includes professionals with experience from major medical device companies, enhancing credibility and expertise [18] - **Future Outlook**: - Strong potential for partnerships in 2026, with ongoing discussions for various technologies [32] This summary encapsulates the key aspects of NeuroOne Medical Technologies as discussed in the conference, highlighting its innovative technology, market potential, financial health, and strategic direction.

Core Insights - Nuwellis, Inc. has completed the acquisition of Rendiatech, Inc., enhancing its capabilities in automated kidney function monitoring technology for critically ill patients [1][2] Group 1: Acquisition Details - The acquisition of Rendiatech allows Nuwellis to access assets previously held by RenalSense Ltd. after its bankruptcy [1] - Rendiatech's technology focuses on automated, continuous renal monitoring, providing real-time data to support clinical decision-making [3] Group 2: Product Integration - The new technology complements Nuwellis' existing Aquadex SmartFlow System, which is designed to manage fluid overload in patients [2] - Continuous renal monitoring is crucial for assessing kidney function and acute kidney injury (AKI), enabling timely clinical interventions [3] Group 3: Strategic Implications - The acquisition aligns with Nuwellis' strategy to enhance solutions for patients in cardiac surgery, critical care, and cardiorenal populations, where effective fluid management is vital [4] - The integration of real-time kidney function monitoring with targeted fluid removal aims to improve patient outcomes by allowing earlier identification and management of fluid balance issues [4]

Core Viewpoint - PAVmed Inc. will host a business update conference call and webcast on March 30, 2026, to discuss its operations and growth strategy, along with the fourth quarter 2025 financial results [1]. Group 1: Conference Call Details - The conference call is scheduled for 8:30 AM ET on March 30, 2026 [1]. - U.S. callers can join by dialing 1-800-836-8184, while international listeners should dial 1-646-357-8785, using the conference call name "PAVmed Business Update" [2]. - A replay of the conference call will be available for 30 days on the investor relations section of the company's website [3]. Group 2: Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors [4]. - The company's subsidiary, Lucid Diagnostics, markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, which are the first commercial tools for early detection of esophageal precancer [4]. - Another subsidiary, Veris Health Inc., focuses on personalized cancer care through remote patient monitoring and is developing an implantable physiological monitor to interface with the Veris Cancer Care Platform [4].

Core Viewpoint - Ascom's 2025 financial year demonstrated significant operational improvements and strategic execution, indicating positive momentum despite ongoing challenges [1] Financial Results Summary - Ascom generated net revenue of CHF 292.1 million in 2025, reflecting a growth of 3.8% at constant currencies and 1.9% at actual currencies compared to CHF 286.7 million in 2024 [4][8] - The company achieved a gross profit of CHF 140.8 million, resulting in a gross margin of 48% [7] - EBITDA increased to CHF 34.3 million, with an EBITDA margin of 11.7%, up from 7.4% in 2024 [7][8] - Group profit rose to CHF 15.1 million, with earnings per share increasing to CHF 0.43 [8] Regional Performance - The USA & Canada region experienced the highest growth at 7.3% at constant currencies, while the South region grew by 4.5% and the North region increased by 1.5% [5] Market Segment Breakdown - The Healthcare sector accounted for 66% of total revenue, while the Enterprise segment represented 28% and the OEM business accounted for 6% [6] Operational Efficiency and Innovation - Ascom underwent a significant organizational redesign, consolidating six regions into three, which improved project execution and customer responsiveness [3] - The company focused on enhancing software capabilities and interoperability, leading to a unified platform that improves operational efficiency [9] Order Backlog and Cash Position - Incoming orders totaled CHF 311.1 million, reflecting a growth of 3.2% at constant currencies, with an order backlog of CHF 310.7 million at the end of 2025 [10] - Ascom's net cash position was CHF 29.6 million as of December 31, 2025, with no outstanding borrowings [11] Outlook for 2026 - Ascom targets low to mid-single-digit revenue growth at constant currencies and an EBITDA margin of 10-12% for fiscal year 2026 [13] - The company is well-positioned to leverage opportunities from digital transformation in healthcare and enterprise markets [12]

Company Overview - Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a key player in the medical technology sector, focusing on advanced silicone breast implants [1] Financial Performance - ESTA's Return on Invested Capital (ROIC) is -12.48%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 9.01%, indicating insufficient returns to cover capital costs [2] - The negative ROIC to WACC ratio for ESTA is -1.39, highlighting the company's challenges in generating adequate returns [2] Comparative Analysis - OrthoPediatrics Corp. (KIDS) has a ROIC of -6.27% and a WACC of 8.86%, resulting in a ROIC to WACC ratio of -0.71, which is better than ESTA's performance [3] - SI-BONE, Inc. (SIBN) shows a ROIC of -10.42% and a WACC of 7.50%, leading to a similar ROIC to WACC ratio of -1.39 as ESTA [3] - Crinetics Pharmaceuticals, Inc. (CRNX) faces a severe situation with a ROIC of -49.33% and a WACC of 4.44%, resulting in a ROIC to WACC ratio of -11.10 [4] - In contrast, LivaNova PLC (LIVN) has a positive ROIC of 10.90% and a WACC of 7.96%, achieving a favorable ROIC to WACC ratio of 1.37, indicating efficient capital utilization [4]